# The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.

> **NCT04691063** · PHASE3 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 486 (estimated)

## Conditions studied

- Small-cell Lung Cancer

## Interventions

- **DRUG:** SHR-1316; Carboplatin; Etoposide；Radiotherapy
- **DRUG:** Palcebo; Carboplatin; Etoposide；Radiotherapy

## Key facts

- **NCT ID:** NCT04691063
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-22
- **Primary completion:** 2025-05-15
- **Final completion:** 2025-05-15
- **Target enrollment:** 486 (ESTIMATED)
- **Last updated:** 2021-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04691063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04691063, "The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04691063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*